| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Methylophiopogonone A targets inflammatory pathways, including NF-κB and MAPK signaling. It modulates reactive oxygen species (ROS) generation. Its anti-inflammatory activity is mediated through the modulation of these signaling pathways, leading to reduced production of pro-inflammatory cytokines.
|
|---|---|
| ln Vitro |
In vitro, Methylophiopogonone A exhibits anti-inflammatory activity. It has antioxidant properties and modulates ROS generation and NF-κB/MAPK-related signaling. These activities suggest potential applications in the treatment of inflammatory diseases.
|
| ln Vivo |
In vivo activity data for Methylophiopogonone A are limited. Its in vitro anti-inflammatory and antioxidant activities suggest potential in vivo efficacy in models of inflammation and oxidative stress. Further in vivo studies are needed to confirm its therapeutic potential.
|
| Enzyme Assay |
In vitro assays for Methylophiopogonone A are conducted to evaluate its anti-inflammatory and antioxidant activities. Anti-inflammatory activity is assessed by measuring the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in LPS-stimulated macrophages using ELISA. NF-κB activation is measured by assessing p65 nuclear translocation or by using luciferase reporter assays. MAPK phosphorylation is assessed by Western blotting.
|
| Cell Assay |
Cellular assays for Methylophiopogonone A are performed using macrophages (e.g., RAW264.7) or other inflammatory cell lines. Cells are treated with compound concentrations ranging from 0.1 to 100 µM for 1-24 hours, followed by LPS stimulation. Cytokine levels in culture supernatants are measured by ELISA. ROS levels are measured using fluorescent probes such as DCFH-DA.
|
| Animal Protocol |
In vivo animal studies for Methylophiopogonone A would typically utilize rodent models of inflammation, such as carrageenan-induced paw edema or LPS-induced endotoxemia. The compound is administered orally or intraperitoneally. Endpoints include inflammatory markers in serum and tissues, and histopathological evaluation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Methylophiopogonone A are not well characterized. The compound has a molecular weight of 340.33 and a molecular formula of C₁₉H₁₆O₆. It is soluble in DMSO (10 mM). Standard PK studies in rodents would be required.
|
| Toxicity/Toxicokinetics |
Toxicological data for Methylophiopogonone A are limited. As a natural product-derived compound, it may have a favorable safety profile. No significant acute toxicity has been reported.
|
| References | |
| Additional Infomation |
Methyl ophiopogon A is a homoflavonoid with the structure 4H-1-benzopyran-4-one, substituted with hydroxyl groups at positions 5 and 7, methyl groups at positions 6 and 8, and a (2H-1,3-benzodioxane-5-yl)methyl group at position 3. It is a plant metabolite, belonging to the homoflavonoid class and is a member of the resorcinol class. Methyl ophiopogon A has been reported in Liriope muscari, Arabidopsis thaliana, and Ophiopogon japonicus.
Methylophiopogonone A is a homoisoflavonoid from Ophiopogon japonicus with anti-inflammatory activity. It modulates ROS generation and NF-κB/MAPK signaling. It has a molecular weight of 340.33 and formula C₁₉H₁₆O₆. It is not clinically approved. |
| Molecular Formula |
C19H16O6
|
|---|---|
| Molecular Weight |
340.3267
|
| Exact Mass |
340.094
|
| CAS # |
74805-90-6
|
| PubChem CID |
10065830
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.454±0.06 g/cm3
|
| Boiling Point |
573.6±50.0 °C at 760 mmHg
|
| Melting Point |
210-211 °C
|
| Flash Point |
211.3±23.6 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.681
|
| LogP |
4.09
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
560
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
AUTZLTCWRDPAPV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H16O6/c1-9-16(20)10(2)19-15(17(9)21)18(22)12(7-23-19)5-11-3-4-13-14(6-11)25-8-24-13/h3-4,6-7,20-21H,5,8H2,1-2H3
|
| Chemical Name |
3-(1,3-benzodioxol-5-ylmethyl)-5,7-dihydroxy-6,8-dimethylchromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~293.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9383 mL | 14.6916 mL | 29.3832 mL | |
| 5 mM | 0.5877 mL | 2.9383 mL | 5.8766 mL | |
| 10 mM | 0.2938 mL | 1.4692 mL | 2.9383 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
